Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 19;50(3):166. doi: 10.3892/or.2023.8603

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Lukoseviciute et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 2. — WST-1 viability assay in NB cell lines after treatment with WEE1 inhibitor MK and PARP inhibitor BMN. Viability of SK-N-AS treated with MK (A), BMN (B) and combination of MK and BMN (C), viability of SK-N-BE(2)-C treated with MK (D), BMN (E) and combination of MK and BMN (F), viability of SK-N-DZ treated with MK (G), BMN (H) and combination of MK and BMN (I), viability of SK-N-FI treated with MK (J), BMN (K) and combination of MK and BMN (L) and viability of SK-N-SH treated with MK (M), BMN (N) and combination of MK and BMN (O) was measured by absorbance 24, 48 and 72 h. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 vs. PBS control at each time point. NB, neuroblastoma; BMN, BMN673; MK, MK-1775; WEE1, WEE1 G2 checkpoint kinase; PARP, poly-ADP-ribose-polymerase.